Editorial: Promises to keep
By Los Angeles Times,
Los Angeles Times
| 01. 17. 2006
AT THE HEART OF CALIFORNIA'S multibillion-dollar experiment in public stem cell research are two promises. One is that such research will save lives. The other is that the scientists conducting it, and the agency funding it, will be accountable. The first is as magnificent as it is exaggerated; the second is more practical but as yet unfulfilled.
That's the bad news. The good news is that there's still time for the state agency set up by Proposition 71, which created a $3-billion bond to fund such research, to make good on its promise. All it will take is compromise, common sense _ and maybe a little litigation. The last of these, at least, is starting to have an effect.
Research in the public interest
Any undertaking this big was bound to have early stumbles, but the first year under the stem cell initiative was especially disappointing. To start, the initiative itself has multiple flaws, most of them related to accountability.
The California Institute of Regenerative Medicine was created by Proposition 71, which also freed it from most public oversight and...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...